NASDAQ:TYME - Tyme Technologies Stock Price, Forecast & News

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Tyme Technologies Inc (NASDAQ:TYME) posted its quarterly earnings results on Monday, November, 4th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. View Tyme Technologies' Earnings History.

Tyme Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, June 10th 2020. View Earnings Estimates for Tyme Technologies.

1 equities research analysts have issued twelve-month price targets for Tyme Technologies' shares. Their forecasts range from $9.50 to $9.50. On average, they anticipate Tyme Technologies' share price to reach $9.50 in the next year. This suggests a possible upside of 603.7% from the stock's current price. View Analyst Price Targets for Tyme Technologies.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.

Headlines about TYME stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tyme Technologies earned a news impact score of -2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for Tyme Technologies.

Tyme Technologies saw a increase in short interest in January. As of January 31st, there was short interest totalling 7,830,000 shares, an increase of 16.3% from the January 15th total of 6,730,000 shares. Based on an average daily volume of 511,300 shares, the days-to-cover ratio is presently 15.3 days. Currently, 19.0% of the shares of the stock are sold short. View Tyme Technologies' Current Options Chain.

Some companies that are related to Tyme Technologies include Atreca (BCEL), Kadmon (KDMN), Vanda Pharmaceuticals (VNDA), Vectura Group (VEGPF), Akero Therapeutics (AKRO), Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Flexion Therapeutics (FLXN), BioXcel Therapeutics (BTAI), Molecular Templates (MTEM), ZIOPHARM Oncology (ZIOP), Clovis Oncology (CLVS), Ardelyx (ARDX), XBiotech (XBIT) and Crinetics Pharmaceuticals (CRNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include OpGen (OPGN), Karyopharm Therapeutics (KPTI), Bausch Health Companies (BHC), Rigel Pharmaceuticals (RIGL), AcelRx Pharmaceuticals (ACRX), MEI Pharma (MEIP), Nabriva Therapeutics (NBRV), Viking Therapeutics (VKTX), Aduro BioTech (ADRO) and Catalyst Pharmaceuticals (CPRX).

Tyme Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Healthcare Value Capital LLC (1.77%), State Street Corp (1.23%), Geode Capital Management LLC (0.61%), UBS Group AG (0.07%), Barclays PLC (0.05%) and Goldman Sachs Group Inc. (0.03%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies.

TYME stock was sold by a variety of institutional investors in the last quarter, including Healthcare Value Capital LLC and State Street Corp. View Insider Buying and Selling for Tyme Technologies.

TYME stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Barclays PLC, Ladenburg Thalmann Financial Services Inc., Geode Capital Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc. and Citigroup Inc.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, Michele Ilene Korfin and Steve Hoffman. View Insider Buying and Selling for Tyme Technologies.

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TYME stock can currently be purchased for approximately $1.35.

Tyme Technologies has a market capitalization of $165.83 million. The company earns $-32,980,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.View Additional Information About Tyme Technologies.

The official website for Tyme Technologies is http://www.tymeinc.com/.

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]